You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDoxepin
Accession NumberDB01142  (APRD00398)
TypeSmall Molecule
GroupsApproved
Description

Doxepin hydrochloride is a dibenzoxepin-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, doxepin does not affect mood or arousal, but may cause sedation. In depressed individuals, doxepin exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as doxepin and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Doxepin has less sedative and anticholinergic effects than amitriptyline. See toxicity section below for a complete listing of side effects. Doxepin may be used to treat depression and insomnia. Unlabeled indications include chronic and neuropathic pain, and anxiety. Doxepin may also be used as a second line agent to treat idiopathic urticaria.

Structure
Thumb
Synonyms
Cidoxepin
Doxepin
Sinequan
Zonalon
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-doxepin - Cap 10mgcapsule10 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Alti-doxepin-cap 25mgcapsule25 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Alti-doxepin-cap 50mgcapsule50 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Alti-doxepin-cap 75mgcapsule75 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-10 - Capcapsule10 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-100 - Capcapsule100 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-150 - Capcapsule150 mgoralPro Doc Limitee1995-12-312009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-25 -capcapsule25 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-50 - Capcapsule50 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepine-75 - Capcapsule75 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-doxepincapsule150 mgoralTeva Canada Limited1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-doxepincapsule100 mgoralTeva Canada Limited1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-doxepincapsule75 mgoralTeva Canada Limited1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-doxepincapsule50 mgoralTeva Canada Limited1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-doxepincapsule25 mgoralTeva Canada Limited1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-doxepincapsule50 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-doxepincapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-doxepincapsule100 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-doxepincapsule75 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Prudoxincream50 mg/gtopicalSmith & Nephew, Inc.2012-12-212015-11-30Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Prudoxincream50 mg/gtopicalHEALTHPOINT, LTD2001-10-012015-11-30Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Prudoxincream50 mg/gtopicalPrestium Pharma, Inc.2015-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rho-doxepin - Cap 25mgcapsule25 mgoralRhodiapharm Inc1995-12-311998-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rho-doxepin - Cap 50mgcapsule50 mgoralRhodiapharm Inc1995-12-311998-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rho-doxepin-10 Mg Capcapsule10 mgoralRhodiapharm Inc1995-12-311998-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Silenortablet3.00 mgoralPaladin Labs Inc2013-01-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Silenortablet6 mg/1oralPernix Therapeutics, LLC2010-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Silenortablet3 mg/1oralPernix Therapeutics, LLC2010-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Silenortablet6.00 mgoralPaladin Labs Inc2013-01-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 100mgcapsule100 mgoralErfa Canada 2012 Inc1975-12-312015-06-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 10mgcapsule10 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 150mgcapsule150 mgoralPfizer Canada Inc1983-12-312000-07-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 25mgcapsule25 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 50mgcapsule50 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sinequan Cap 75mgcapsule75 mgoralErfa Canada 2012 Inc1977-12-312015-06-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Triadapin Cap 100mgcapsule100 mgoralAventis Pharma Inc1985-12-312002-07-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Triadapin Cap 10mgcapsule10 mgoralAventis Pharma Inc1985-12-312001-07-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Triadapin Cap 25mgcapsule25 mgoralAventis Pharma Inc1985-12-312001-07-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Triadapin Cap 50mgcapsule50 mgoralAventis Pharma Inc1985-12-312002-07-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Triadapin Cap 75mgcapsule75 mgoralAventis Pharma Inc1985-12-312002-07-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Zonaloncream50 mg/gtopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.1994-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zonaloncream50 mg/gtopicalPrestium Pharma, Inc.2015-03-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zonaloncream50 mg/gtopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zonalon Cream 5%cream5 %topicalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxepincapsule50 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-doxepincapsule25 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-doxepincapsule150 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-doxepincapsule100 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-doxepincapsule10 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-doxepincapsule75 mgoralApotex Inc1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Doxepin Hydrochloridecapsule25 mg/1oralPhysicians Total Care, Inc.1996-04-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralTYA Pharmaceuticals1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralMedsource Pharmaceuticals1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridesolution, concentrate10 mg/mLoralTeva Pharmaceuticals USA Inc1987-11-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralAidarex Pharmaceuticals LLC2012-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule150 mg/1oralSTAT Rx USA LLC1987-11-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralbryant ranch prepack2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule150 mg/1oralPar Pharmaceutical Inc1987-11-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralCardinal Health2011-08-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralH.J. Harkins Company, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule150 mg/1oralAv Kare, Inc.2012-08-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2012-01-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule150 mg/1oralPhysicians Total Care, Inc.2007-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralPhysicians Total Care, Inc.2003-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2010-12-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule150 mg/1oralREMEDYREPACK INC.2015-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.1995-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralRebel Distributors Corp1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridesolution10 mg/mLoralMorton Grove Pharmaceuticals, Inc.1995-02-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2010-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralPhysicians Total Care, Inc.1996-10-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralRebel Distributors Corp1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridesolution10 mg/mLoralSilarx Pharmaceuticals, Inc1998-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralMedsource Pharmaceuticals1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralbryant ranch prepack2012-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.1999-09-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2010-12-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralUnit Dose Services2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule100 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule75 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule50 mg/1oralA S Medication Solutions Llc2012-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Doxepin Hydrochloridecapsule10 mg/1oralbryant ranch prepack2012-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AdapinPennwaIt
AponalPfizer
CuratinNot Available
DoxepineShou Chan
QuitaxonLexphar
SinequanPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Doxepin Hydrochloride
Thumb
  • InChI Key: MHNSPTUQQIYJOT-UHFFFAOYSA-N
  • Monoisotopic Mass: 315.138992038
  • Average Mass: 315.837
DBSALT000059
Categories
UNII5ASJ6HUZ7D
CAS number1668-19-5
WeightAverage: 279.3761
Monoisotopic: 279.162314299
Chemical FormulaC19H21NO
InChI KeyInChIKey=ODQWQRRAPPTVAG-BOPFTXTBSA-N
InChI
InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-
IUPAC Name
dimethyl(3-{9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxepines
Sub ClassDibenzoxepines
Direct ParentDibenzoxepines
Alternative Parents
Substituents
  • Dibenzoxepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationDoxepin is used for the treatment of depression and/or anxiety. It can also be used for chronic urticaria and in the management of pain.
PharmacodynamicsDoxepin, a tricyclic antidepressant of the dibenzoxepin type, is used to treat depression and anxiety and, topically, pruritus associated with eczema. Doxepin has substantial anticholinergic and sedative effects. The E (trans)-isomer is more active as a serotonin reuptake inhibitor while the Z-isomer acts as a sedative.
Mechanism of actionThe mechanism of action of doxepin is not completely understood. It is thought that like amitriptyline, doxepin enhances the actions of norepinephrine and serotonin by blocking their reuptake at the neuronal membrane. However, doxepin weakly inhibits the reuptake of dopamine. Doxepin may also act on histamine H1-receptors, resulting in sedative effects, and β-adrenergic receptors. It is also an antagonist of 5-hydroxytryptamine (serotonin) receptors, alpha-1 adrenergic receptor, and muscarinic cholinergic receptors.
AbsorptionWell-absorbed from the GI tract. Peak plasma concentrations occur within 2 hours of oral administration.
Volume of distributionNot Available
Protein bindingDoxepin and desmethyldoxepin is 80% protein bound. It is also a lipophillic drug and is capable of crossing the blood-brain-barrier.
Metabolism

Extensively metabolized in the liver via the same pathways as other TCAs. N-demethylation produces an active metabolite, N-desmethyldoxepin. CYP2D6 specifically hydroxylates the E-isomer.

SubstrateEnzymesProduct
Doxepin
N-desmethyldoxepinDetails
Doxepin
Not Available
Doxepin N-oxideDetails
Doxepin
Not Available
(E)-2-hydroxydoxepinDetails
Doxepin
(Z)-N-desmethyldoxepinDetails
Doxepin
(E)-N-desmethyldoxepinDetails
Doxepin
Not Available
Doxepin-N-oxideDetails
Doxepin
Not Available
(E)-2-O-glucuronyldoxepinDetails
N-desmethyldoxepin
Not Available
Didesmethyl doxepinDetails
Doxepin N-oxide
Not Available
Doxepin N-oxide glucuronideDetails
(E)-2-hydroxydoxepin
Not Available
Hydroxydoxepin glucuronideDetails
N-desmethyldoxepin
Hydroxydesmethyl doxepinDetails
(E)-2-hydroxydoxepin
Not Available
Hydroxydesmethyl doxepinDetails
Hydroxydesmethyl doxepin
Not Available
Hydroxydesmethyl doxepin glucuronideDetails
Route of eliminationNot Available
Half life6 - 24.5 hours
ClearanceNot Available
ToxicityLD50=26 (mg/kg) (in mice, iv); LD50=16 (mg/kg) (in rats, iv); Cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8108
P-glycoprotein substrateSubstrate0.8147
P-glycoprotein inhibitor IInhibitor0.8147
P-glycoprotein inhibitor IIInhibitor0.8214
Renal organic cation transporterInhibitor0.7883
CYP450 2C9 substrateNon-substrate0.7846
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7475
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.917
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6362
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.8461
Rat acute toxicity3.2478 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5346
hERG inhibition (predictor II)Inhibitor0.6959
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral10 mg/1
Capsuleoral100 mg/1
Capsuleoral150 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Solutionoral10 mg/mL
Solution, concentrateoral10 mg/mL
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral25 mg
Capsuleoral50 mg
Capsuleoral75 mg
Tabletoral3 mg/1
Tabletoral3.00 mg
Tabletoral6 mg/1
Tabletoral6.00 mg
Creamtopical50 mg/g
Creamtopical5 %
Prices
Unit descriptionCostUnit
Zonalon 5% Cream 45 gm Tube190.13USD tube
Zonalon 5% Cream 30 gm Tube144.29USD tube
Doxepin hcl powder8.88USD g
Doxepin 150 mg capsule3.33USD capsule
Prudoxin 5% cream3.05USD g
Sinequan 100 mg Capsule1.22USD capsule
Novo-Doxepin 150 mg Capsule1.18USD capsule
Sinequan 75 mg Capsule0.93USD capsule
Zonalon 5% cream0.89USD g
Doxepin HCl 150 mg capsule0.87USD capsule
Apo-Doxepin 100 mg Capsule0.68USD capsule
Novo-Doxepin 100 mg Capsule0.68USD capsule
Sinequan 50 mg Capsule0.64USD capsule
Doxepin 50 mg capsule0.57USD capsule
Doxepin HCl 100 mg capsule0.56USD capsule
Novo-Doxepin 75 mg Capsule0.52USD capsule
Apo-Doxepin 75 mg Capsule0.52USD capsule
Doxepin HCl 75 mg capsule0.43USD capsule
Apo-Doxepin 50 mg Capsule0.36USD capsule
Novo-Doxepin 50 mg Capsule0.36USD capsule
Sinequan 25 mg Capsule0.35USD capsule
Doxepin 10 mg capsule0.32USD capsule
Sinequan 10 mg Capsule0.28USD capsule
Doxepin HCl 50 mg capsule0.25USD capsule
Doxepin HCl 25 mg capsule0.23USD capsule
Doxepin 75 mg capsule0.21USD capsule
Doxepin HCl 10 mg capsule0.21USD capsule
Apo-Doxepin 10 mg Capsule0.2USD capsule
Apo-Doxepin 25 mg Capsule0.19USD capsule
Novo-Doxepin 25 mg Capsule0.19USD capsule
Doxepin 25 mg capsule0.18USD capsule
Doxepin 100 mg capsule0.14USD capsule
Doxepin HCl 10 mg/ml Concentrate0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point265 °C at 2.00E-01 mm HgPhysProp
water solubility31.6 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.29SANGSTER (1994)
logS-3.4ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0319 mg/mLALOGPS
logP4.08ALOGPS
logP3.84ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity98.24 m3·mol-1ChemAxon
Polarizability32.47 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox, “LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME.” U.S. Patent US20090074862, issued March 19, 2009.

US20090074862
General References
  1. Virtanen R, Iisalo E, Irjala K: Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh). 1982 Aug;51(2):159-64. Pubmed
  2. Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. Pubmed
  3. Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. Pubmed
  4. Negro-Alvarez JM, Carreno-Rojo A, Funes-Vera E, Garcia-Canovas A, Abellan-Aleman AF, Rubio del Barrio R: Pharmacologic therapy for urticaria. Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):36-51. Pubmed
  5. Sansone RA, Sansone LA: Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008 Dec;5(12):16-9. Pubmed
  6. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. Pubmed
External Links
ATC CodesN06AA12
AHFS Codes
  • 28:16.04.28
  • 84:08.00
PDB EntriesNot Available
FDA labelDownload (588 KB)
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Doxepin can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Acetophenazine.
Acetylsalicylic acidDoxepin may increase the antiplatelet activities of Acetylsalicylic acid.
AclidiniumAclidinium may increase the anticholinergic activities of Doxepin.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Doxepin.
AmisulprideThe risk or severity of adverse effects can be increased when Doxepin is combined with Amisulpride.
AmphetamineDoxepin may increase the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Aripiprazole.
AzelastineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Doxepin.
BatimastatThe serum concentration of Doxepin can be increased when it is combined with Batimastat.
BenzquinamideThe risk or severity of adverse effects can be increased when Doxepin is combined with Benzquinamide.
Botulinum Toxin Type ADoxepin may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDoxepin may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
BuprenorphineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe metabolism of Doxepin can be decreased when combined with Bupropion.
ButabarbitalThe metabolism of Doxepin can be increased when combined with Butabarbital.
ButethalThe metabolism of Doxepin can be increased when combined with Butethal.
CarbamazepineThe metabolism of Doxepin can be increased when combined with Carbamazepine.
CarphenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Carphenazine.
CathinoneDoxepin may increase the stimulatory activities of Cathinone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorpromazine.
ChlorpropamideDoxepin may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorprothixene.
CimetidineThe metabolism of Doxepin can be decreased when combined with Cimetidine.
Cimetropium BromideDoxepin may increase the anticholinergic activities of Cimetropium Bromide.
CinacalcetThe serum concentration of Doxepin can be increased when it is combined with Cinacalcet.
CitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
ClozapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Clozapine.
CobicistatThe serum concentration of Doxepin can be increased when it is combined with Cobicistat.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.
DarunavirThe serum concentration of Doxepin can be increased when it is combined with Darunavir.
DesmopressinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxepin.
DicoumarolDoxepin may increase the anticoagulant activities of Dicoumarol.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Doxepin.
DofetilideDoxepin may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DuloxetineDuloxetine may increase the serotonergic activities of Doxepin.
EluxadolineDoxepin may increase the activities of Eluxadoline.
EscitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
EthanolDoxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FencamfamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fencamfamine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.
FlupentixolThe risk or severity of adverse effects can be increased when Doxepin is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxepin.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Doxepin is combined with Glucagon recombinant.
GoserelinDoxepin may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Doxepin.
HaloperidolThe risk or severity of adverse effects can be increased when Doxepin is combined with Haloperidol.
HeptabarbitalThe metabolism of Doxepin can be increased when combined with Heptabarbital.
HexobarbitalThe metabolism of Doxepin can be increased when combined with Hexobarbital.
HydrocodoneDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
IcosapentDoxepin may increase the antiplatelet activities of Icosapent.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Doxepin.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Doxepin.
IsoflurophateThe serum concentration of Doxepin can be increased when it is combined with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Doxepin.
LeuprolideDoxepin may increase the QTc-prolonging activities of Leuprolide.
LinezolidLinezolid may increase the serotonergic activities of Doxepin.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Doxepin.
LithiumLithium may increase the neurotoxic activities of Doxepin.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Doxepin.
LoxapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Loxapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
MesoridazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Mesoridazine.
MethohexitalThe metabolism of Doxepin can be increased when combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Methotrimeprazine.
Methylene blueDoxepin may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Doxepin.
MetyrosineDoxepin may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Doxepin.
MidodrineDoxepin may increase the activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Doxepin.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
MirabegronThe risk or severity of adverse effects can be increased when Doxepin is combined with Mirabegron.
MolindoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Doxepin is combined with Morphine.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
NicorandilDoxepin may increase the hypotensive activities of Nicorandil.
OlanzapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Doxepin is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Orciprenaline.
OrphenadrineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PaliperidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Paliperidone.
PanobinostatThe serum concentration of Doxepin can be increased when it is combined with Panobinostat.
ParaldehydeDoxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
Peginterferon alfa-2bThe serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Doxepin can be increased when combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
PerphenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Doxepin.
PimozideThe risk or severity of adverse effects can be increased when Doxepin is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Piperacetazine.
Potassium ChlorideDoxepin may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleDoxepin may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Doxepin.
PrimidoneThe metabolism of Doxepin can be increased when combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Doxepin.
PromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Quetiapine.
QuinidineDoxepin may increase the QTc-prolonging activities of Quinidine.
RamosetronDoxepin may increase the activities of Ramosetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Doxepin is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Doxepin is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Risperidone.
RitonavirThe metabolism of Doxepin can be decreased when combined with Ritonavir.
RopiniroleDoxepin may increase the sedative activities of Ropinirole.
RotigotineDoxepin may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.
SecobarbitalThe metabolism of Doxepin can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Doxepin.
SertindoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Doxepin.
SimeprevirThe serum concentration of Doxepin can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
St. John's WortThe metabolism of Doxepin can be increased when combined with St. John&#39;s Wort.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Doxepin.
SuvorexantDoxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Doxepin can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Doxepin.
TerbinafineThe metabolism of Doxepin can be decreased when combined with Terbinafine.
ThalidomideDoxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Doxepin is combined with Thiothixene.
TiclopidineThe metabolism of Doxepin can be decreased when combined with Ticlopidine.
TiotropiumDoxepin may increase the anticholinergic activities of Tiotropium.
TopiramateThe risk or severity of adverse effects can be increased when Doxepin is combined with Topiramate.
TramadolDoxepin may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Doxepin.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Doxepin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Triflupromazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Doxepin.
Valproic AcidThe serum concentration of Doxepin can be increased when it is combined with Valproic Acid.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Doxepin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziprasidone.
ZolpidemDoxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Doxepin is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

Targets

1. Histamine H1 receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

  1. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. Pubmed
  2. Tran VT, Lebovitz R, Toll L, Snyder SH: [3H]doxepin interactions with histamine H1-receptors and other sites in guinea pig and rat brain homogenates. Eur J Pharmacol. 1981 Apr 9;70(4):501-9. Pubmed
  3. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K: Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci. 2004 Aug;20(3):803-10. Pubmed
  4. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. Pubmed
  5. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. Pubmed
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  7. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed
  8. Singh H, Becker PM: Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. Pubmed
  9. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Histamine H2 receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Histamine H2 receptor P25021 Details

References:

  1. Beil W, Hannemann H, Sewing KF: Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion. Pharmacology. 1988;36(3):198-203. Pubmed
  2. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

3. Sodium-dependent noradrenaline transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed

4. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed

5. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. Pubmed
  3. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed

6. 5-hydroxytryptamine receptor 2B

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2B P41595 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. Pubmed

7. 5-hydroxytryptamine receptor 2C

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P28335 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. Pubmed

8. Muscarinic acetylcholine receptor M1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M1 P11229 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed
  3. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. Pubmed
  4. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

9. Muscarinic acetylcholine receptor M2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M2 P08172 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. Pubmed
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

10. Muscarinic acetylcholine receptor M3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M3 P20309 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. Pubmed
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

11. Muscarinic acetylcholine receptor M4

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M4 P08173 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. Pubmed
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

12. Muscarinic acetylcholine receptor M5

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M5 P08912 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. Pubmed
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. Pubmed

13. Alpha-1A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. Pubmed

14. Alpha-1B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. Pubmed

15. Alpha-1D adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1D adrenergic receptor P25100 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. Pubmed
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. Pubmed

16. 5-hydroxytryptamine receptor 1A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. Pubmed

17. Alpha-2A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

18. Alpha-2B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2B adrenergic receptor P18089 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

19. Alpha-2C adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2C adrenergic receptor P18825 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

20. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. Pubmed

21. 5-hydroxytryptamine receptor 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 6 P50406 Details

References:

  1. Roth, BL; Driscol, J (12 January 2011). PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 20 October 2013.

22. Histamine H4 receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Histamine H4 receptor Q9H3N8 Details

References:

  1. Roth, BL; Driscol, J (12 January 2011). PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 20 October 2013.

23. Potassium voltage-gated channel subfamily H member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC: Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol. 2007 Aug 1;74(3):425-37. Epub 2007 May 3. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P: Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4. Pubmed
  2. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004 Jul;60(5):329-36. Epub 2004 May 28. Pubmed
  3. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. Pubmed
  4. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. Pubmed
  5. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. Pubmed
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. Pubmed
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. Pubmed
  2. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. Pubmed

Carriers

1. Alpha-1-acid glycoprotein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
Alpha-1-acid glycoprotein 1 P02763 Details

References:

  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13